---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023419"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:55:43.186672+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Dermata Therapeutics pivots to OTC; plans acne kit launch mid-2026, reports Q3 cash $4.7M

## Summary
- Cash and cash equivalents of $4.7M as of Sep 30, 2025; expected to fund operations into Q2 2026.
- R&D expenses dropped to $0.5M in Q3 2025 from $2.4M in Q3 2024 as XYNGARI Phase 3 trial concluded.
- Strategic pivot to OTC dermatology; first product is a once-weekly acne kit using Spongilla technology, launch mid-2026.
- Company plans to sell OTC acne kit directly to consumers, estheticians, and dermatologists for in-office use.

## SEC filing metadata
- accession: 0001493152-25-023419
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/0001493152-25-023419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315225023419/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023419
- JSON: https://secwatch.observer/filing/0001493152-25-023419.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023419.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.